Grant: CIHR Fellowship
Direct Payment
$125,000.00
Using A Novel Conditional Gene Knockout Strategy To Examine The Role Of VEGF Signaling In The Cellular And Behavioral Actions Of Antidepressant Treatment
EF 2010-11
Résumé
Depression is a debilitating illness affecting 1 in 7 Canadians at some point in their life. Because of its high prevalence and economic cost, depression imposes a profound health care burden that not only affects the individual but permeates throughout all avenues of social, work, and family life. Although several antidepressant drugs are available, chronic administration is necessary for therapeutic effects to be achieved and only some patients (<50%) show improvement. However, despite these limitations, significant progress has been made in identifying molecules and genes important in antidepressant action. One promising candidate in this regard is vascular endothelial growth factor (VEGF). Several studies have found that various antidepressant treatments increase VEGF expression in brain regions involved in depression, and that the induction of VEGF appears to be important in producing the therapeutic effects of these treatments. Although these findings suggest a role of VEGF in antidepressant action, it is presently unclear if the loss of VEGF actually results in the development of depression. In this study, a novel strategy involving genetic and viral manipulations will be used to selectively delete the VEGF gene in neurons (or other cell types) within brain regions important in depression (e.g. hippocampus, medial prefrontal cortex). These genetically modified mice will be tested for depressive and anxiety behavior and the effects of various antidepressants examined to determine which specific source of VEGF (e.g. neuron, astrocyte, endothelial) is necessary for producing the behavioral and cellular effects of these treatments. It is anticipated that these studies will provide important information about the role of VEGF-signaling in the cellular and molecular mechanism action of antidepressants that one day could help identify new antidepressant compounds that can rapidly and safely act in high proportion of patients with depression.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Connecticut, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
224857
Name
Fournier Neil M
Region
Connecticut
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Allied Health Professionals - Fellowships
Projecttitle
Using A Novel Conditional Gene Knockout Strategy To Examine The Role Of VEGF Signaling In The Cellular And Behavioral Actions Of Antidepressant Treatment
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$125,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Aging; Antidepressants; Behaviour; Conditional Gene Knockout; Depression; Hippocampus; Neurotrophic Factors; Recombinant Viruses; Stress; Vascular Endothelial Growth Factor
Abstract
Depression is a debilitating illness affecting 1 in 7 Canadians at some point in their life. Because of its high prevalence and economic cost, depression imposes a profound health care burden that not only affects the individual but permeates throughout all avenues of social, work, and family life. Although several antidepressant drugs are available, chronic administration is necessary for therapeutic effects to be achieved and only some patients (<50%) show improvement. However, despite these limitations, significant progress has been made in identifying molecules and genes important in antidepressant action. One promising candidate in this regard is vascular endothelial growth factor (VEGF). Several studies have found that various antidepressant treatments increase VEGF expression in brain regions involved in depression, and that the induction of VEGF appears to be important in producing the therapeutic effects of these treatments. Although these findings suggest a role of VEGF in antidepressant action, it is presently unclear if the loss of VEGF actually results in the development of depression. In this study, a novel strategy involving genetic and viral manipulations will be used to selectively delete the VEGF gene in neurons (or other cell types) within brain regions important in depression (e.g. hippocampus, medial prefrontal cortex). These genetically modified mice will be tested for depressive and anxiety behavior and the effects of various antidepressants examined to determine which specific source of VEGF (e.g. neuron, astrocyte, endothelial) is necessary for producing the behavioral and cellular effects of these treatments. It is anticipated that these studies will provide important information about the role of VEGF-signaling in the cellular and molecular mechanism action of antidepressants that one day could help identify new antidepressant compounds that can rapidly and safely act in high proportion of patients with depression.
Competitiondate
201102
Approvedterm2
2 yrs 6 mths
Pinamesdelim
Fournier, Neil M
Approvedterm
2 ans 6 mois
Cihrcontribution2
~ $125,000~ $0~